期刊文献+

首诊为急性缺血性脑卒中患者的骨髓增殖性肿瘤相关基因突变研究 被引量:3

Mutation analysis of myeloproliferative neoplasms associated genes in patients first diagnosed as acute ischemic stroke
原文传递
导出
摘要 目的 分析首诊为急性缺血性脑卒中(AIS)患者的骨髓增殖性肿瘤(MPN)相关JAK2、MPL和CALR基因突变发生情况.方法 收集378例AIS患者的外周血标本和临床资料.用等位基因特异性PCR和Sanger基因测序法检测患者基因组DNA中JAK2 V617F、JAK2 Exon12、MPL Exon10和CALR Exon9基因突变,并分析突变阳性患者的病史、临床资料、外周血细胞分类计数以及其他辅助检查结果.结果 共检测到5例(1.3%)患者JAK2 V617F突变阳性,1例(0.3%)CALR基因突变阳性,总阳性率为1.6%.其中2例JAK2 V617F突变阳性患者的外周血血红蛋白水平达到MPN的诊断标准.结论 约1.6%的首诊为AIS的患者可检测到JAK2 V617F或CALR突变,这部分患者可能处于MPN的早期阶段. Objective To detect mutations of JAK2,MPL and CALR genes which are associated with myeloproliferative neoplasms (MPN) in patients first diagnosed as acute ischemic stroke (AIS).Methods Peripheral blood and detailed clinical data of 378 AIS patients were collected.Allele specific PCR and Sanger sequencing were used to detect mutations of JAK2 V617F,JAK2 Exon12,MPL Exon10 and CALR Exon9.For patients in whom mutations were detected,detailed clinical data and auxiliary examination and laboratory test results were further analyzed.Results A total of 6 (1.6 %) patients harbored mutations in the genes detected,5 of them (1.3 %) were positive of JAK2 V617F mutation and the other one (0.3 %) carried mutation in the CALR gene.The hemoglobin contents of 2 patients who were positive of JAK2 V617F mutation met the diagnostic criteria of MPN.Conclusion About 1.6 % patients who were first diagnosed as AIS harbor mutations of JAK2 V617F or CALR,and they may at the early stage of MPN.
出处 《白血病.淋巴瘤》 CAS 2015年第7期428-430,436,共4页 Journal of Leukemia & Lymphoma
基金 山东省科技发展计划(2014GGH218041) 山东省临床重点专科建设项目
关键词 急性缺血性脑卒中 骨髓增殖性肿瘤 JAK2 CALR MPL Acute ischemic stroke Myeloproliferative neoplasm JAK2 CALR MPL
  • 相关文献

参考文献16

  • 1Reikvam H, Tiu RV. Venous thromhoembolism in patients with essenlial thrombocylhemia and polycythemia vera [ J ]. Leukemia, 2012, 26(4) : 563-571.
  • 2中国急性缺血性脑卒中诊治指南2010[J].中华神经科杂志,2010,43(2):146-153. 被引量:3406
  • 3Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid lissues [ M ]. Lyon:IARC, 2008 : 31-66.
  • 4Deleve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver [ J [, Hepatology, 2009, 49 ( 5 ) : 1729-1764.
  • 5刘红星,童春荣,蔡鹏,顾江英,林跃辉,张英,滕文,王赫,朱平.真性红细胞增多症和原发性血小板增多症JAK2 V617F基因纯合突变克隆分析[J].首都医科大学学报,2008,29(2):113-117. 被引量:13
  • 6Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somalic mutations of creticulin in myeloproliferative neoplasms [ J ]. N Engl J Med, 2013, 369( 25 ) : 2379-2390.
  • 7Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [ J ]. Cancer Cell, 2005, 7 ( 4 ) : 387-397.
  • 8Kralovies R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders [ J] N Engl J Med, 2005, 352 ( 17 ) : 1779-1790.
  • 9Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera [ J ]. J Biol Chem, 2005, 280 ( 24 ) : 22788-22792.
  • 10Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms [ J ]. Leukemia, 2008, 22 ( 1 ) : 14-22.

二级参考文献41

共引文献3417

同被引文献41

  • 1Jones AV, Kreil S, Zoi K, et al. Widespread occmTence of the JAK2 V617F mutation in chronic myeloproliferative disorders [ J ]. Blood, 2005, 106 ( 6 ) : 2162-2168.
  • 2Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferalive neoplasms [ J ]. N Engl J Med, 2013, 369( 25 ) : 2379-2390.
  • 3Tefferi A, Pardanani A. Genetics: CALR mutations and a new diagnostic algorithm for MPN [J ]. Nat Rev Clin Oncol, 2014, 11 ( 3 ) : 125-126.
  • 4Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thromboeythemia [ J ]. Blood, 2013, 121(10) : 1701-1711.
  • 5Reikvam H, Tiu RV. Venous thromboerabohsra in patients with essential thrombocythemia and polycythemia vera [ J ]. Leukemia, 2012, 26(4 ): 563-571.
  • 6Andriani A, Latagliata R, Cedronc M, et al. Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: a retrospective analysis of 623 patients series with long follow-up [ J ]. Blood ( ASH annual meeting abstract ), 2014, 124 ( 21 ) : 1855.
  • 7Palandri F, PoIverelli N, Latagliata R, et aL Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis [ J ]. Blood ( ASH annual meeting abstract ), 2014, 124(21 ) : 3190.
  • 8Pieri L, Guglielmelli P, Primignani M, et al. Splanchnic vein thrombosis associated with myeloproliferalive neoplasms: a study of the AGIMM & IWG-MRT Groups in 519 subjects [ J ]. Blood ( ASH annual meeting abstrt ), 2014, 124 ( 21 ) : 3163.
  • 9Finazzi MC, Carobbio A, Cervantes F, et at. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofihrosis [ J ]. Leukemia, 2015, 29 ( 5 ) : 1209- 1210.
  • 10Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia [ J]. Blood, 2014, 123 ( 10 ) : 1552-1555.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部